Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vermeire

Showing results (41-50 of 137) with videos related to

Pageof 14
Sort By:
Expert Opinion on Biological Therapy|May 24, 2019
Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's diseaseG Bislenghi, A Wolthuis, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|June 25, 2015
Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel diseaseT Lobatón, M Ferrante, P Rutgeerts, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2017
Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel diseaseU Mahadevan, S Vermeire, K Lasch, et al.
Inflammatory Bowel Diseases|August 29, 2000
Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneityS Vermeire, M Peeters, R Vlietinck, et al.
Research in Veterinary Science|August 31, 2010
The effect of medetomidine on the regional cerebral blood flow in dogs measured using Technetium-99m-Ethyl Cysteinate Dimer SPECTT Waelbers, K Peremans, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|February 7, 2017
Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control studyS Van Steenbergen, S Bian, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' replyU Mahadevan, S Vermeire, K Lasch, et al.
Gut|February 19, 2011
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatmentN Vande Casteele, V Ballet, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|July 13, 2018
Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' replyU Mahadevan, S Vermeire, K Lasch, et al.
Gut|April 13, 2006
Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn's diseaseS Joossens, M Pierik, A Rector, et al.
Pageof 14

Showing results (41-50 of 137) with videos related to

Sort By:
Pageof 14
Expert Opinion on Biological Therapy|May 24, 2019
Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's diseaseG Bislenghi, A Wolthuis, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|June 25, 2015
Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel diseaseT Lobatón, M Ferrante, P Rutgeerts, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2017
Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel diseaseU Mahadevan, S Vermeire, K Lasch, et al.
Inflammatory Bowel Diseases|August 29, 2000
Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneityS Vermeire, M Peeters, R Vlietinck, et al.
Research in Veterinary Science|August 31, 2010
The effect of medetomidine on the regional cerebral blood flow in dogs measured using Technetium-99m-Ethyl Cysteinate Dimer SPECTT Waelbers, K Peremans, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|February 7, 2017
Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control studyS Van Steenbergen, S Bian, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' replyU Mahadevan, S Vermeire, K Lasch, et al.
Gut|February 19, 2011
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatmentN Vande Casteele, V Ballet, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|July 13, 2018
Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' replyU Mahadevan, S Vermeire, K Lasch, et al.
Gut|April 13, 2006
Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn's diseaseS Joossens, M Pierik, A Rector, et al.
Pageof 14